A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2493-2503

  Montamat Sicotte, Damien J ^a,b   Millington, Kerry A ^a   Willcox, Carrie R ^b   Hingley Wilson, Suzie ^a   Hackforth, Sarah ^c   Innes, John ^c   Kon, Onn Min ^d   Lammas, David A ^b   Minnikin, David E ^b   Besra, Gurdyal S ^b   Willcox, Benjamin E ^b   Lalvani, Ajit ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD1B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MYCOLIC ACID;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; LUNG TUBERCULOSIS; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MENINGITIS; PHENOTYPE; PRIORITY JOURNAL; PSOAS ABSCESS; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS;

ACUTE DISEASE; ADAPTIVE IMMUNITY; ADULT; AGED; ANTIGENS, BACTERIAL; ANTIGENS, CD1; ANTITUBERCULAR AGENTS; BCG VACCINE; CELL WALL; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VIRULENCE; YOUNG ADULT;

EID: 79957907714     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46216     Document Type: Article

References (64)

1. WHO. Global tuberculosis control; epidemiology, strategy, financing. In: World Health Report 2009. Geneva, Switzerland: World Health Organization; 2009:6-33.
2. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med. 2005;11(4 suppl):S33-S44. (Pubitemid 40562302)
3. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol. 2009;7(1):81-87.
4. Colditz GA, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698-702. (Pubitemid 24061706)
5. Kaufmann SH, Baumann S, Nasser Eddine A. Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis. 2006;10(10):1068-1079. (Pubitemid 44519343)
6. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004; 22:817-890. (Pubitemid 38680443)
7. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature. 1994;372(6507):691-694.
8. Sieling PA, et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science. 1995;269(5221):227-230.
9. Moody DB, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature. 2000;404(6780):884-888.
10. Dascher CC, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol. 2003;15(8):915-925. (Pubitemid 36987289)
11. Kawashima T, et al. Cutting edge: major CD8 T cell response to live bacillus Calmette-Guerin is mediated by CD1 molecules. J Immunol. 2003; 170(11):5345-5348. (Pubitemid 36617817)
12. Ulrichs T, Moody DB, Grant E, Kaufmann SH, Porcelli SA. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun. 2003;71(6):3076-3087. (Pubitemid 36637529)
13. Gilleron M, et al. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J Exp Med. 2004;199(5):649-659. (Pubitemid 38316432)
14. Layre E, et al. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. Chem Biol. 2009;16(1):82-92.
15. Schaible UE, Kaufmann SH. CD1 and CD1-restricted T cells in infections with intracellular bacteria. Trends Microbiol. 2000;8(9):419-425.
16. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29-63.
17. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 1994;264(5157):382-388. (Pubitemid 24178901)
18. Barry CE 3rd, Mdluli K. Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Trends Microbiol. 1996;4(7):275-281. (Pubitemid 26251780)
19. Moody DB, Porcelli SA. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol. 2003;3(1):11-22.
20. Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol. 2009;102:1-94.
21. Jackman RM, et al. The tyrosine-containing cytoplasmic tail of CD1b is essential for its efficient presentation of bacterial lipid antigens. Immunity. 1998;8(3):341-351. (Pubitemid 28188894)
22. Sugita M, et al. Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs. Science. 1996;273(5273):349-352. (Pubitemid 26250261)
23. Willcox BE, Willcox CR, Dover LG, Besra G. Structures and functions of microbial lipid antigens presented by CD1. Curr Top Microbiol Immunol. 2007; 314:73-110.
24. Behar SM, Porcelli SA. CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol. 2007;314:215-250.
25. Stenger S, Niazi KR, Modlin RL. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J Immunol. 1998;161(7):3582-3588.
26. Moody DB, et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science. 1997;278(5336):283-286.
27. + T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells from leprosy lesions. J Immunol. 2000;164(9):4790-4796.
28. + alpha beta T cell pool. J Immunol. 1999;162(1):366-371.
29. Ochoa MT, et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med. 2001; 7(2):174-179.
30. Stenger S, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science. 1997; 276(5319):1684-1687. (Pubitemid 27421972)
31. Stenger S, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998; 282(5386):121-125. (Pubitemid 28471143)
32. De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol. 2005;5(6):485-496. (Pubitemid 40835036)
33. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev. 2005;18(1):81-101. (Pubitemid 40170662)
34. Barry CE 3rd, et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res. 1998;37(2-3):143-179.
35. Dubnau E, et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol. 2000;36(3):630-637. (Pubitemid 30258847)
36. Ojha AK, et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008;69(1):164-174. (Pubitemid 351832764)
37. Felio K, et al. CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J Exp Med. 2009;206(11):2497-2509.
38. + T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis. 2003;187(2):243-250.
39. + memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis. 2006;194(7):984-992.
40. Pathan AA, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol. 2001;167(9):5217-5225. (Pubitemid 33009758)
41. McShane H, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004; 10(11):1240-1244. (Pubitemid 39540442)
42. Lalvani A, et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis. 1999; 180(5):1656-1664. (Pubitemid 29506471)
43. + memory T cells. J Exp Med. 1997;186(6):859-865.
44. Godkin AJ, Thomas HC, Openshaw PJ. Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol. 2002; 169(4):2210-2214. (Pubitemid 34857690)
45. Gadola SD, et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat Immunol. 2002;3(8):721-726.
46. Casey R, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS One. 2010;5(12):e15619.
47. Millington KA, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. 2007;178(8):5217-5226. (Pubitemid 46595306)
48. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131(6):1898-1906.
49. Lalvani A. Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? Clin Infect Dis. 2004;38(5):757-759. (Pubitemid 38333875)
50. Grant EP, et al. Fine specificity of TCR complementarity-determining region residues and lipid antigen hydrophilic moieties in the recognition of a CD1-lipid complex. J Immunol. 2002; 168(8):3933-3940. (Pubitemid 34298397)
51. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature. 1992;360(6404):593-597. (Pubitemid 23000710)
52. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol. 2004;22:599-623. (Pubitemid 38680435)
53. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581-620. (Pubitemid 34293435)
54. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708-712.
55. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174(2):1037-1045. (Pubitemid 40094300)
56. Caccamo N, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One. 2009;4(5):e5528.
57. Uldrich AP, et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hypo-responsiveness to further antigenic challenge. J Immunol. 2005;175(5):3092-3101. (Pubitemid 41170529)
58. Parekh VV, et al. Glycolipid antigen induces longterm natural killer T cell anergy in mice. J Clin Invest. 2005;115(9):2572-2583. (Pubitemid 41266220)
59. Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol. 2008;181(4):2292-2302.
60. Dosanjh DP, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med. 2008;148(5):325-336. (Pubitemid 351665463)
61. Minnikin DE, Polgar N. The methoxymycolic and ketomycolic acids from human tubercle bacilli. Chem Commun (London). 1967;22:1172-1174.
62. Minnikin DE, Polgar N. The mycolic acids from human and avian tubercle bacilli. Chem Commun (London). 1967;18:916-918.
63. Besra GS. Preparation of cell-wall fractions from mycobacteria. Methods Mol Biol. 1998;101:91-107.
64. Vuola JM, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol. 2005;174(1):449-455. (Pubitemid 40007434)